Cardiff Oncology (CRDF) Cash from Investing Activities (2011 - 2025)

Cardiff Oncology has reported Cash from Investing Activities for 15 years, with the latest figure at $10.7 million in Q4 2025.

• Quarterly Cash from Investing Activities rose 138.28% year-over-year to $10.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 90.22% YoY) and the FY2025 annual result came in at $1.3 million, down 90.22% from the prior year.
• Cash from Investing Activities improved to $10.7 million in Q4 2025 per CRDF's latest filing, from $10.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $18.4 million in Q1 2022 and troughed at -$111.7 million in Q1 2021.
• A 5-year average of -$2.1 million and a median of $6.1 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 5326.62% in 2021, down 15328.07% in 2021.
• Over 5 years, Cash from Investing Activities stood at -$8.8 million in 2021, then jumped by 179.83% to $7.0 million in 2022, then soared by 93.18% to $13.6 million in 2023, then plunged by 66.74% to $4.5 million in 2024, then soared by 138.28% to $10.7 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $10.7 million, $10.2 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.